AUS
NZ
UK
CA
USA
IND
ANGLE PLC (LSE:AGL) is a leader in the field of liquid biopsy, renowned for its cutting-edge sample-to-answer solutions. The company’s flagship technology, the Parsortix® system, is a patent-protected platform that allows for the harvesting of circulating tumour cells (CTCs) from blood samples. Notably, it is the first and only FDA-cleared medical device for this purpose, specifically for use in metastatic breast cancer.
Strategic Partnership with NuProbe USA
ANGLE recently announced a significant partnership with NuProbe USA, aimed at accelerating the development of a groundbreaking "pan-cancer" molecular sequencing assay. This innovative test is designed to integrate seamlessly with ANGLE's Parsortix liquid biopsy system, enabling it to be utilized across various cancer types.
The collaboration will leverage both technologies to allow for the analysis of circulating tumour cell DNA (CTC-DNA) as well as a combined analysis of circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) from a single blood sample. This dual approach is expected to offer a comprehensive overview of a cancer's genetic profile, potentially enhancing diagnosis and treatment options.
Collaboration with Recursion Pharmaceuticals
In addition to its partnership with NuProbe, ANGLE has secured an agreement with Nasdaq-listed Recursion Pharmaceuticals Inc. This collaboration will involve a fully funded pilot study, as Recursion focuses on utilizing artificial intelligence and automation for experimental biology and cellular disease model testing. This partnership signifies ANGLE's commitment to innovative research and development in cancer diagnostics.
Progress and Recognition
ANGLE has recently published data supporting the FDA approval of its Parsortix PC1 system for harvesting circulating tumour cells, with findings appearing in the Journal of Experimental & Clinical Cancer Research. This recognition highlights the rigorous scientific foundation upon which ANGLE's technologies are built.
Andrew Newland, the CEO of ANGLE, and his team have successfully developed a unique cancer diagnostic technology, positioning the company on the brink of commercial success. A recent fundraising initiative raised £9.3 million, which is anticipated to facilitate the company’s progression towards cash flow break-even by the end of next year.
ANGLE PLC is at the forefront of innovation in cancer diagnostics, with its advanced liquid biopsy technology and strategic partnerships poised to enhance patient outcomes. As the company continues to develop its capabilities in molecular analysis, it remains a significant player in the evolving landscape of cancer treatment and diagnosis.
